Literature DB >> 30081182

The association between thyroid cancer and insulin resistance, metabolic syndrome and its components: A systematic review and meta-analysis.

De-Tao Yin1, Huanan He2, Kun Yu3, Jing Xie4, Mengyuan Lei3, Runsheng Ma3, Hongqiang Li3, Yongfei Wang3, Zhen Liu3.   

Abstract

BACKGROUND: Thyroid cancer is rapidly increasing in incidence worldwide in the past several decades, same as the incidence of metabolic syndrome. We performed a system review and meta-analysis of the association between metabolic syndrome, its components and insulin resistance and thyroid cancer incidence.
METHODS: We searched several computer-assisted databases PUBMED, EMBASE and ISI Web of Science to identify studies published before 31st January 2018. Every study must report either risk estimates of thyroid cancer incidence with 95% confidence interval (CI) or related data can speculate. Two investigators independently identified eligible studies and extracted data. Evaluating the summaries of relative risk estimates use both fixed and random effects methods.
RESULTS: We found 42 articles met the inclusion criteria of this review. There is an increased risk for thyroid cancer for patients with insulin resistance (relative risk [RR] = 1.59, 95%confidence interval [CI] = 1.12-2.27, P = 0.01), dysglycemia (RR = 1.40, 95%CI = 1.15-1.70,P < 0.001), high BMI (RR = 1.35,95%CI = 1.23-1.48,P < 0.001) and hypertension(RR = 1.34,95%CI = 1.22-1.47, p < 0.001). However, patients with dyslipidemia, both total cholesterol (RR = 1.09, 95%CI = 0.98-1.21, P = 0.13) and triglyceride (RR = 1.01, 95%CI = 0.91-1.12, P = 0.82) was not associated with thyroid cancer.
CONCLUSIONS: Our meta-analysis showed Insulin Resistance, dysglycemia, high BMI and hypertension significantly increased the thyroid cancer risk. These results may help identify people with high risk of thyroid cancer and change to healthy life style.
Copyright © 2018 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Insulin resistance; Meta-analysis; Metabolic syndrome; Risk factor; Thyroid cancer

Mesh:

Year:  2018        PMID: 30081182     DOI: 10.1016/j.ijsu.2018.07.013

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  17 in total

1.  Pituitary neuroendocrine tumors and differentiated thyroid cancer: do metabolic and inflammatory risk factors play roles?

Authors:  G Cortês Nascimento; A G P de Araujo Cortês Nascimento; C de Maria Ribeiro Veiga Parente; V P Rodrigues; R S de Sousa Azulay; V C de Carvalho Rocha; S da Silva Pereira Damianse; M Magalhães; M Dos Santos Faria; M B Gomes
Journal:  J Endocrinol Invest       Date:  2020-07-17       Impact factor: 4.256

2.  The Inverse Association of Serum Magnesium with Papillary Thyroid Cancer in Thyroid Nodules: a Cross-Sectional Survey Based on Thyroidectomy Population.

Authors:  Huaijin Xu; Xiaodong Hu; Jiefei Li; Zhimei Nie; Shaoyang Kang; Hongzhou Liu; Yuhan Wang; Xiaomeng Jia; Zhaohui Lyu
Journal:  Biol Trace Elem Res       Date:  2022-10-13       Impact factor: 4.081

3.  Metabolic Score for Insulin Resistance Is Correlated to Adipokine Disorder and Inflammatory Activity in Female Knee Osteoarthritis Patients in a Chinese Population.

Authors:  Lu Ding; Yu-Hang Gao; Ye-Ran Li; Yi-Fan Huang; Xin-Yu Wang; Xin Qi
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-19       Impact factor: 3.168

4.  Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Ana P Santos; Ana C Santos; Clara Castro; Luís Raposo; Sofia S Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P Monteiro
Journal:  Cancers (Basel)       Date:  2018-08-27       Impact factor: 6.639

5.  Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Luigi Barrea; Giovanna Muscogiuri; Roberta Modica; Barbara Altieri; Gabriella Pugliese; Roberto Minotta; Antongiulio Faggiano; Annamaria Colao; Silvia Savastano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-18       Impact factor: 5.555

6.  Favorable function of Ectonucleoside triphosphate diphosphohydrolase 1 high expression in thyroid carcinoma.

Authors:  Jun-Hua Luo; Yun-Hua Zhu; Cheng Xiang
Journal:  Hereditas       Date:  2021-08-31       Impact factor: 3.271

7.  Association between metabolic syndrome and clinicopathological features of papillary thyroid cancer.

Authors:  Jun-Long Song; Ling-Rui Li; Xi-Zi Yu; Ling Zhan; Zhi-Liang Xu; Juan-Juan Li; Sheng-Rong Sun; Chuang Chen
Journal:  Endocrine       Date:  2021-11-26       Impact factor: 3.925

Review 8.  Obesity and Thyroid Cancer Risk: An Update.

Authors:  Fabiana Franchini; Giuseppe Palatucci; Annamaria Colao; Paola Ungaro; Paolo Emidio Macchia; Immacolata Cristina Nettore
Journal:  Int J Environ Res Public Health       Date:  2022-01-20       Impact factor: 3.390

9.  The role of metabolic setting in predicting the risk of early tumour relapse of differentiated thyroid cancer (DTC).

Authors:  Chiara Mele; Marina Caputo; Maria Teresa Samà; Valentina Bullara; Maria Grazia Mauri; Flavia Prodam; Gianluca Aimaretti; Loredana Pagano; Paolo Marzullo
Journal:  Eur J Clin Nutr       Date:  2020-06-09       Impact factor: 4.016

10.  Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: a study of 1579 cases: a retrospective study.

Authors:  Huijuan Wang; Pingping Wang; Yu Wu; Xiukun Hou; Zechun Peng; Weiwei Yang; Lizhao Guan; Linfei Hu; Jingtai Zhi; Ming Gao; Xiangqian Zheng
Journal:  PeerJ       Date:  2020-09-08       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.